Organisation paid for research Program year 2025 Source: CMS Open Payments

Arthritis Northwest, PLLC

Neither a doctor nor a teaching hospital

Research payments

$1,085,585

56 payments

Through program year 2025, Arthritis Northwest, PLLC is reported as receiving $1,085,585 in research payments, across 56 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $199,375 8
2024 Research $351,249 7
2023 Research $365,736 20
2022 Research $84,604 7
2021 Research $3,935 2
2020 Research $17,127 7
2019 Research $63,560 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $342,699 4 payments
  2. Alexion Pharmaceuticals, Inc. $303,527 2 payments
  3. Novartis Pharmaceuticals Corporation $215,484 8 payments
  4. E.R. Squibb & Sons, L.L.C. $88,490 10 payments
  5. AstraZeneca UK Limited $87,338 12 payments
  6. Ucb SA $26,832 4 payments
  7. Sanofi US Services Inc. $13,057 6 payments
  8. Sun Pharmaceutical Industries Inc. $8,157 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $342,699 4 payments
  2. Eneboparatide - Calypso study which is a pivotal phase 3 study investigational therapeutic peptide with a novel mechanism of action for hypoparathyroidism $303,527 2 payments
  3. A Randomized, Double-Blind, Placebo Controlled, 3-Arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (Neptunus-2) $142,528 3 payments
  4. A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome $60,457 2 payments
  5. The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus $55,881 6 payments
  6. A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) $41,779 1 payment
  7. A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus $27,753 3 payments
  8. The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE $20,503 1 payment
  9. A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. $15,916 1 payment
  10. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica $12,532 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record